

2025 GNIPST BULLETIN (Pharmacy)

Volume-2, Issue- 1

Special Attraction Page



GURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



Table of Contents

1	Message from Director and Principal	1
2	Recent Researches	2
3	New Drug Approvals	3-4
4	Clinical Trial News	5
5	Disease Outbreak News	6
6	Campus News	7
7	Special Pages	8-9
8	Game Time	10-11



MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt New Year greetings to all of you. May this new year bring you abundant joy, success, and fulfillment.

At our esteemed institution, we remain steadfast in our commitment to fostering an environment that champions academic excellence, innovation, and holistic development. With a dedicated focus on the pursuit of Pharmaceutical Sciences, we continue to nurture inquisitive minds, inspire critical thinking, and equip our students with the skills necessary for their success. As we step into 2025, we are excited to continue growing, evolving, and upholding our mission to provide top-quality education, while promoting research and innovation. We are deeply grateful for your ongoing support, involvement, and collaboration with Guru Nanak Institute of Pharmaceutical Science and Technology.

Here's to a year filled with progress and new achievements!

Prof. (Dr.) Abhijit Sengupta

MESSAGE FROM HONORABLE PRINCIPAL

I extend my heartfelt New Year wishes to all our students, faculty, staff, and partners. May this year bring you abundant health, happiness, and success.

Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST) has consistently demonstrated its dedication to delivering high-quality pharmacy education. As we approach 2025, our commitment to achieving excellence in both academic and professional development remains unwavering. Founded in 2005 and recognized by the Pharmacy Council of India (PCI), GNIPST stands as a leader in pharmacy education within West Bengal. We take immense pride in being the pioneering pharmacy institution in the region to attain accreditation from both NAAC and NBA. Furthermore, GNIPST has earned recognition as an NIRF-ranked pharmacy institute, achieving an impressive 74th position in 2024.

We believe that the values, traditions, and educational facilities at GNIPST, along with our unwavering focus on innovation and research, will continue to guide our students to greater achievements. As we move forward, we invite those passionate about pharmacy to choose this field as a career and join us for an academically enriching and rewarding experience.

Here's to a successful and inspiring 2025, filled with opportunities to grow, learn, and excel.

Prof. (Dr.) Lopamudra Datta





RECENT RESEARCHES



WHO prequalifies diagnostic test to support safer administration of P. vivax malaria treatments

MORE INFO

www.who.int/

On 18 December 2024, the World Health Organization (WHO) prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency which can help to safely deliver WHO-recommended treatments to prevent relapse of Plasmodium vivax (P. vivax) infection. The prequalification of this G6PD diagnostic test marks a significant milestone in facilitating safe and effective P. vivax malaria treatment, reaffirming WHO's dedication to ensuring equitable access to life-saving health solutions globally. Some 500 000 people die each year from malaria, most of them children.

Trends of acute respiratory infection, including human metapneumovirus, in the Northern Hemisphere

MORE INFO

www.who.int/

In many countries of the Northern Hemisphere, trends in acute respiratory infections increase at this time of year. These increases are typically caused by seasonal epidemics of respiratory pathogens such as seasonal influenza, respiratory syncytial virus (RSV), and other common respiratory viruses, including human metapneumovirus (hMPV), as well as mycoplasma pneumoniae. Many countries conduct routine surveillance for acute respiratory infections and common respiratory pathogens. Currently, in some countries in the temperate Northern hemisphere, influenza-like illness (ILI) and/or acute respiratory infection (ARI) rates have increased in recent weeks and are above baseline levels, following usual seasonal trends. Seasonal influenza activity is elevated in many countries in the Northern hemisphere. Where surveillance data is available, trends in RSV detections currently vary by region with decreases reported in most regions except in North America. Recently, there has been interest in hMPV cases in China including suggestions of hospitals being overwhelmed. hMPV is a common respiratory virus found to circulate in many countries in winter through to spring, although not all countries routinely test and publish data on trends in hMPV. While some cases can be hospitalized with bronchitis or pneumonia, most people infected with hMPV have mild upper respiratory symptoms similar to the common cold and recover after a few days. Based on data published by China, covering the period up to 29 December 2024, acute respiratory infections have increased during recent weeks and detections of seasonal influenza, rhinovirus, RSV, and hMPV, particularly in northern provinces of China have also increased.

FDA

NEW DRUG APPROVALS

Unloxyt (cosibelimab- ipdl) Injection

- **Company:** Checkpoint Therapeutics, Inc.
- **Date of Approval:** December 13, 2024
- **Treatment for:** Squamous Cell Carcinoma



Steqeyma (ustekinumab- stba) Injection

- **Company:** Celltrion USA
- **Date of Approval:** December 17, 2024
- **Treatment for:** Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis



Tryngolza (olezarsen) Injection

- **Company:** Ionis Pharmaceuticals, Inc.
- **Date of Approval:** December 19, 2024
- **Treatment for:** Familial Chylomicronemia Syndrome



Alhemo (concizumab-mtci) Injection

- **Company:** Novo Nordisk
- **Date of Approval:** December 20, 2024
- **Treatment for:** Hemophilia A with Inhibitors, Hemophilia B with Inhibitors



Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection

- **Company:** Bristol-Myers Squibb Company
- **Date of Approval:** December 27, 2024
- **Treatment for:** Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer.



Alyftrek (deutivacaftor, tezacaftor and vanzacaftor)

- **Company:** Vertex Pharmaceuticals Incorporated
- **Date of Approval:** December 20, 2024
- **Treatment for:** Cystic Fibrosis



Symvess for Surgical Vascular Implantation

- **Company:** Humacyte, Inc.
- **Date of Approval:** December 19, 2024
- **Treatment for:** Revascularization Procedures



LATEST GENERIC DRUG APPROVALS



- Approved: December 3, 2024 - Mylan Pharmaceuticals Inc.
- Treatment for: Schizophrenia; Bipolar I Disorder
- Generic for: Abilify Maintena

Aripiprazole for Extended Release Injectable Suspension 300 mg/vial and 400 mg/vial

- Approved: December 6, 2024 - Rubicon Research Private Limited
- Treatment for: Spasticity
- Generic for: Ozobax

Baclofen Oral Solution 5 mg/5 mL

- Approved: December 9, 2024 - B. Braun Medical Inc.
- Treatment for: Metabolic Acidosis
- Generic for: Tham

Tromethamine Injection 18 g/500 mL (3.6 g/100 mL)

- Approved: December 9, 2024 - BWXT Medical Ltd.
- Use: Diagnostic
- Generic for: AdreView

Iobenguane Sulfate I-123 Injection 10 mCi/5 mL (2 mCi/mL)

- Approved: December 17, 2024 - FDC Limited
- Treatment for: Bacterial Infections
- Generic for: Suprax Tablets

Cefixime Tablets 400 mg

Raltegravir Potassium Tablets 400mg (base)

- Approved: December 19, 2024 - Hetero Labs Limited
- Treatment for: HIV Infection
- Generic for: Isentress

Liraglutide Subcutaneous Injection 18 mg/3 mL (6 mg/mL)

- Approved: December 23, 2024 - Hikma Pharmaceuticals USA Inc.
- Treatment for: Type 2 Diabetes
- Generic for: Victoza

Deutetrabenazine Tablets 6 mg, 9 mg and 12 mg

- Approved: December 26, 2024 - Aurobindo Pharma Limited
- Treatment for: Huntington's Disease
- Generic for: Austedo

Prucalopride Succinate Tablets 1 mg (base) and 2 mg (base)

- Approved: December 26, 2024 - Novitium Pharma LLC
- Treatment for: Chronic Idiopathic Constipation
- Generic for: Motegrity

Exenatide Injection 300 mcg/1.2 mL (250 mcg/mL) and 600 mcg/2.4 mL (250 mcg/mL)

- Approved: November 19, 2024 - Amneal Pharmaceuticals LLC
- Treatment for: Type 2 Diabetes
- Generic for: Byetta



CLINICAL TRIAL NEWS



01.

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation

NEW YORK, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the successful completion of its Phase 3 clinical program evaluating AXS-05 (dextromethorphan-bupropion), a novel, oral, investigational NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor, in Alzheimer's disease agitation, and results of the ACCORD-2, ADVANCE-2, and long-term safety trials in this indication.

02.

CagriSema Demonstrates Superior Weight Loss in Adults with Obesity or Overweight in the REDEFINE 1 Trial

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people with obesity or overweight with one or more comorbidities and a mean baseline body weight of 106.9 kg.

03.

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

BOSTON--(BUSINESS WIRE)--Dec. 19, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective Nav1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (LSR). The study met its primary endpoint with statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS).

04.

Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Concept Achieved In Cardiovascular Disease Study

Malmö, Sweden 18 December 2024 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the completion of the study of the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (the "Research Group"). The preliminary results showed that PILA PHARMA's lead candidate, the TRPV1 antagonist, XEN-D0501, significantly reduced Abdominal Aorta Aneurysm growth in mice, establishing preclinical proof-of-concept.

05.

Pilatus Biosciences Inc. Receives Orphan Drug Designation from FDA for PLT012 in Treatment of Liver and Intrahepatic Bile Duct Cancer

December 12, 2024 -- Pilatus Biosciences Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for the treatment of liver and intrahepatic bile duct cancer (HCC/ICC). This milestone, achieved in November 2024, signals a significant step forward in the development of innovative therapies for patients suffering from these challenging malignancies.

06.

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza

GAITHERSBURG, Md., Dec. 10, 2024. Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced that the first participants have been dosed in its COVID-19-Influenza Combination (CIC) and stand-alone seasonal influenza Phase 3 trial. The trial will evaluate the immunogenicity and safety of the CIC and stand-alone seasonal influenza vaccine candidates compared to Novavax's updated 2024-2025 COVID-19 vaccine (NVX-CoV2705) and a licensed seasonal influenza vaccine comparator in adults aged 65 and older.

DISEASE OUTBREAK NEWS (DONS)

December, 2024

Acute respiratory infections complicated by malaria (previously undiagnosed disease) - Democratic Republic of the Congo

27 December 2024

This is an update to the Disease Outbreak News on Undiagnosed disease in the Democratic Republic of the Congo published on 8 December 2024 (now named acute respiratory infections complicated by malaria). It includes updated epidemiological investigation information and preliminary laboratory results. On 29 November, an alert was raised by local health zone authorities of Panzi health zone in Kwango province after an increase in deaths, particularly among children under five years of age, following febrile illness. Enhanced epidemiological surveillance was rapidly implemented, which in the absence of a clear diagnosis was based on the detection of syndromic cases of febrile illnesses with cough, body weakness, with one of a number of other symptoms compatible with acute respiratory and febrile illnesses. This resulted in a rapid increase in the number of cases meeting the definition, with a total of 891 cases reported as of 16 December. However, the weekly number of reported deaths (48 deaths reported over the period) has remained relatively stable. As of 16 December, laboratory results from a total of 430 samples indicated positive results for malaria, common respiratory viruses (Influenza A (H1N1, pdm09), rhinoviruses, SARS-COV-2, Human coronaviruses, parainfluenza viruses, and Human Adenovirus). While further laboratory tests are ongoing, together these findings suggest that a combination of common and seasonal viral respiratory infections and falciparum malaria, compounded by acute malnutrition led to an increase in severe infections and deaths, disproportionately affecting children under five years of age. Multidisciplinary rapid response teams have been deployed to investigate the event and strengthen the response. Efforts are ongoing to address the health needs in Panzi health zone. Enhanced surveillance in the community and within health facilities continues.

**MORE
INFO**

<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON547>

Marburg virus disease - Rwanda

20 December 2024

On 20 December 2024, after two consecutive incubation periods (total of 42 days) since the second negative PCR test was conducted on 7 November for the last confirmed Marburg case, and without a new confirmed case reported, the Ministry of Health of Rwanda declared the end of the Marburg virus disease (MVD) outbreak, as per the WHO recommendations. The outbreak had been declared on 27 September 2024. As of 19 December 2024, 66 confirmed cases, 15 deaths with a case fatality ratio (CFR) of 23%, and 51 recovered cases have been reported. The last confirmed case was reported on 30 October 2024. WHO through its country office and development partners provided technical and financial support to the government to contain this outbreak. The risk of re-emergence of MVD still remains even after the official declaration of the end of the outbreak, linked to viral persistence in body fluids (mostly semen) of recovered patients and the animal reservoir in the country. WHO encourages maintaining early case detection and care capacities in addition to sustaining the ability to quickly respond, also underscoring the importance of the recovered patient program, psychosocial support, and continued risk communication and community engagement.

**MORE
INFO**

<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON548>

CAMPUS NEWS

Ayan Das, a student of M. Pharm, 2nd year, who was named Player of the Tournament at the Sardar Jodh Singh Memorial Cricket Tournament. Ayan's exceptional all-around performance, leadership, and commitment to the game made him stand out as the top player of the entire tournament. His contribution was vital in our team's success and victory.



Arnab Mukherjee, a M.Pharm 2nd-year student, who was named Man of the Match in the Final of the Sardar Jodh Singh Memorial Cricket Tournament. His outstanding performance, incredible skill, and sheer determination played a pivotal role in securing victory for our team in the final match.



GNIPST celebrated World Meditation Day 2024 on 20th December 2024 at the GNIPST Auditorium. Meditation has numerous benefits for mental clarity, stress reduction, and overall well-being, and we wanted to share this incredible practice with our community.



GNIPST Cricket Team Crowned Champions!

We were thrilled to announce that **Titas Das**, a student of B. Pharm, 3rd year, was the Top Scorer of the Sardar Jodh Singh Memorial Cricket Tournament. Her incredible talent and relentless effort on the field made a significant impact throughout the tournament, leading our team with the highest number of runs.

We are ecstatic to announce that the GNIPST Cricket Team has emerged as the Champion in the prestigious JIS SAMMAN 2025 (Sardar Jodh Singh Memorial Cricket Tournament)



Congratulations to **Dr. Talamika Chakraborty**, our esteemed faculty member, on being awarded her PhD. We were incredibly proud of your achievement and wish you continued success in your academic and professional journey.

NATIONAL YOUTH DAY: HONORING SWAMI VIVEKANANDA'S LEGACY

Swami Vivekananda's birthday, celebrated on January 12th as National Youth Day in India, commemorates the life and teachings of one of the greatest spiritual leaders and philosophers. Known for his immense contribution to Indian philosophy and spirituality, Swami Vivekananda continues to inspire generations with his ideals of courage, wisdom, and selfless service.

The day is observed with enthusiasm, especially among the youth, through events such as seminars, speeches, cultural activities, and discussions that highlight his principles. Educational institutions and youth organizations actively participate in celebrating this occasion to encourage young minds to embody his vision.

Significance of National Youth Day:

- **Empowerment of Youth:** The day emphasizes the potential of young individuals as agents of change and progress in society.
- **Promotion of Universal Values:** It highlights Vivekananda's teachings on unity, equality, and spirituality, transcending cultural and religious barriers.
- **Inspiration for Personal Growth:** His ideals encourage self-confidence, perseverance, and a commitment to lifelong learning.
- **Focus on Nation-Building:** Swami Vivekananda's belief in youth as the backbone of a strong nation underscores the importance of active participation in societal development.
- **Celebration of Indian Heritage:** The day reaffirms the significance of India's rich cultural and spiritual traditions, which Vivekananda proudly represented on the global stage.



"ভালোবাসা দাও, সেবা দাও, সাহায্য দাও, যতটুকু তোমার কাছে আছে সব দিয়ে দাও,
কিন্তু সাবধান, বিনিময়ে কিছু চেয়োনা তাহলেই দুঃখ পাবে"

-----স্বামী বিবেকানন্দ



Empowering Dreams: The Journey of "Amra Sobai Raja" an NGO run by Madhurima Sengupta

"Aamra Sobai Raja – Cultural Society" is more than an NGO; it is a movement, a sanctuary of hope, and a beacon of transformation. This remarkable organization strives to uplift underprivileged children in Maoist-affected regions, offering them the tools to break free from cycles of despair and embrace lives of dignity, knowledge, and peace. At the heart of this initiative is **Madhurima Sengupta**, a consultant psychologist, special educator, and tireless humanitarian.

Her work focuses on providing these children with education and basic necessities, helping them understand the transformative power of knowledge. By steering them away from the shadow of insurgency, she empowers them to reintegrate into mainstream society and envision a future filled with peace and opportunity.



Currently collaborating with three CRPF battalions in Bastar, Madhurima's efforts are a testament to her vision of a harmonious society. Her dedication has earned her numerous accolades from prestigious organizations, and her inspiring story has even been featured on the celebrated platform of Dadagiri. Beyond her impactful work, Madhurima is cherished for her empathetic and selfless nature, always extending her support to those in need.



Madhurima, married to Mr. Tamal Sarkar, an SDPO in Chanditala, has poured her heart and soul into establishing and nurturing Aamra Sobai Raja. Over the years, her unwavering commitment has turned this NGO into a lifeline for children in the conflict-ridden districts of Bastar, including Chandameta, Bijapur, Sukma, and Dantewada.




Madhurima Sengupta's journey is a powerful reminder that change begins with one compassionate heart and an unyielding spirit. Through Aamra Sobai Raja, she continues to illuminate countless lives, proving that the greatest gift we can offer the world is hope.



madhu.sengupta18@gmail.com

GNIPST GAME TIME



Rearrange the words (Drug names)

Amazing facts : All the drugs name starting with A

- CAEFNCALOE

Its 100 MG Tablet is a painkiller which provides relief from pain, stiffness, and swelling due to various conditions related to your bone and joints.

- NLOXIACMLII

It is a penicillin antibiotic used to treat bacterial infections, including bronchitis, pneumonia, and infections of the ear, nose, throat, skin, and urinary tract and highly effective in treating bacterial infections.

- MORHNICZTIAY

Its medication may cause serious skin reactions and may cause a certain type of allergic reaction called angioedema.

- NPINTRAO

It is a tropane alkaloid generally used to reduce pain and inflammation and it is an antimuscarinic agent used to treat bradycardia (low heart rate), reduce salivation and bronchial secretions

- VRIOLCCYA

It is an antiviral drug and it slows the growth and spread of the herpes virus but it will not cure herpes.

Stay tuned for to the next edition for a shout out to fastest correct answers!


Submit your answer



or




GNIPST GAME TIME





Answer for Crossword PH-3


**Christmas Crossword Puzzle
Answer Key**


Down


1 


2 

3 


6 


8 


9 


11 


Across


4 


5 

7 

10 

11 

12 

13 

Cheers to the Victor!

Volume -1, Issue -6



Debanjan Bhattacharya

B.Pharm, 3rd Semester

Guru Nanak Institute of Pharmaceutical Science and Technology

Editor- in- Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamura Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major
Recruiters



**Latest
news**



www.gnipst.ac.in



www.facebook.com



www.instagram.com



www.linkedin.com



www.youtube.com



api.whatsapp.com